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Abstract Background: Botulinum neurotoxin type A (BoNT/A) is the active substance
in preparations used for the highly effective treatment of neurologic disorders
such as cervical dystonia, blepharospasm, or spasticity, as well as other indica-
tions such as axillary and palmar hyperhidrosis, and urologic disorders.
Objective: To determine the amount of BoNT/A protein present in pharma-
ceutical preparations of Botox, Dysport, and Xeomin, which are identi-
cal with Vistabel, Azzalure, and Bocouture, respectively.
Methods:Rabbit and guinea pig antibodies raised against the 150kDBoNT/A
neurotoxin purified from Clostridium botulinum type A, strain ATCC 3502
(‘Hall strain’), were used in a sensitive sandwich ELISA to determine the
overall mean concentration of the 150 kD neurotoxin present in four batches
of Botox (C2344C3, C2384C3, C2419, and C2385), two batches of Dys-
port (678F and 689X) and three batches of Xeomin (61111, 70604, and
81 208). The specific neurotoxin potency, defined as the potency or biologic
activity (units) per mass of neurotoxin protein (ng), was calculated based on
the overall mean concentration of BoNT/A neurotoxin.
Results: Overall, the mean concentration of BoNT/A neurotoxin in Botox
was 0.73 ng per 100 unit vial (coefficient of variation [CV] = 3.5%), 3.24 ng per
500 unit vial of Dysport, corresponding to 0.65 ng in 100 units (CV = 11.4%),
and 0.44 ng per 100 unit vial of Xeomin (CV = 1.9%). The specific potency of
the 150 kD BoNT/A neurotoxin was calculated as 137 units/ng for Botox,
154 units/ng Dysport, and 227 units/ng Xeomin.
Conclusions: The current study has shown that of the three products,
Xeomin contains the highest specific neurotoxin activity, followed by Dys-
port, with Botox having the lowest specific activity. This result suggests
that Xeomin contains only active neurotoxin in contrast with Botox, which
is likely to contain additional denatured/inactive neurotoxin.
Background
Botulinum neurotoxin type A (BoNT/A) is
the active substance in preparations used for
the highly effective treatment of neurologic dis-
orders such as cervical dystonia,[1] blepharo-
spasm, or spasticity, as well as other indications
such as axillary and palmar hyperhidrosis,[2] and
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urologic disorders.[3] BoNT/A containing ther-
apeutics are also used in aesthetic dermatology to
treat facial wrinkles (e.g. glabella lines).[4]
There are several BoNT/A containing products
on the market: Botox/Vistabel (Allergan Inc.,
Irvine, CA, USA), Dysport/Azzalure (Ipsen,
Slough, UK/Galderma, Paris, France), and
Xeomin/Bocouture (NT 201; Merz Pharma-
ceuticals GmbH, Frankfurt, Germany). In all three
products, the neurotoxin is derived from the iden-
tical Hall strain of Clostridium botulinum type A.
For the following discussion, these products will be
referred to as Botox, Dysport, and Xeomin, re-
gardless of their clinical indication because the pro-
duct compositions do not differ between indications.
The BoNT/A protein has a molecular weight
of 150 kD, consisting of a light chain (50 kD) and
a heavy chain (100 kD); both chains have differ-
ent functions in the neurotoxin’s mechanism of
action.[5] Whereas Xeomin contains only the
150 kD neurotoxin, the 150 kD neurotoxin in
Botox and Dysport is part of a complex with
other proteins (complexing proteins), which play
no role in the mechanism of action. Botox is
composed of a 900 kD complex,[6] with one mol-
ecule of the 150 kD neurotoxin per complex.[7]
The biochemical composition of Dysport is
unknown. In an early publication, it was reported
that a similar purification process to that used for
the drug substance in Dysport produces a mix-
ture composed of the L complex (600 kD) and M
complex (300 kD).[8] These findings were later
supplemented by protein composition analyses of
the drug substance in Dysport.[9]
The biologic activity of all BoNT/A contain-
ing products is given in units relating to the dose
that is lethal to 50% ofmice tested (LD50); however,
the assay procedure used to determine biologic
activity can differ between companies. Indeed,
the most informative comparisons of BoNT/A
containing products have been made in clinical
studies. In a 16-week, randomized, double-blind,
non-inferiority trial in 463 patients with cervical
dystonia,[10] Xeomin was shown to be as effective
as Botox with a comparable adverse event pro-
file when a clinical conversion ratio of 1U : 1U
was used. Moreover, in a double-blind, non-
inferiority trial in 300 patients with blepharospasm,
treatment with Xeomin was as effective as and
as safe as Botox (using a 1U : 1U conversion
ratio) when assessed by the Jankovic Rating
Scale.[11] This equipotency of Botox andXeomin,
when used at a clinical conversion ratio of 1U : 1U,
was also confirmed in a comparative trial in
the treatment of glabellar frown lines in 381 pa-
tients.[12] The 1U : 1U ratio was not unexpected
because both products have demonstrated the
same activity in a potency assay, which showed
that five different batches of Botox contained a
mean of 101.7 – 6.2 LD50 units per vial and five
different batches of Xeomin contained a mean
of 103.0 – 5.7 LD50 units per vial.[13] Thus, both
clinical and preclinical analyses have demonstra-
ted a 1 : 1 ratio between Botox and Xeomin.[14]
In contrast, the conversion ratio between Dys-
port and Botox or Xeomin is not yet clear.
Conversion ratios of up to 6 : 1 (Dysport :Botox)
have been suggested.[15]
The amount of clostridial protein in Botox
and Dysport is known - one vial of Botox con-
tains 5 ng of clostridial protein per 100 unit vial,[16]
whereas one vial of Dysport contains 4.35 ng of
clostridial protein per 500 unit vial,[9] although
earlier publications from the manufacturer stated
there were 12.5 ng per vial (500 units).[17] Xeomin
is reported to contain approximately 0.6 ng of
clostridial protein per 100 unit vial.[14]
The amount of the 150 kD neurotoxin (i.e. the
active substance) in Botox and Dysport is not
published. There are two important reasons to
know both the amount of clostridial protein and
the amount of the 150 kD neurotoxin in these
preparations. Firstly, accompanying proteins or
impurities may stimulate the immune response
against the therapeutic agent;[18] and secondly,
the dose of the antigen (i.e. the injected amount
of neurotoxin protein itself), as well as the in-
jected amount of denatured/inactive neurotoxin,
determines the immune response. Therefore, the
aim of this study is to determine the concentra-
tion of the 150 kD neurotoxin in Botox, Dys-
port, and Xeomin using a sensitive sandwich
ELISA.
A similar study was carried out with Botox
and Dysport but the results were reported
anonymously.[19]
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Materials and Methods
Materials
The incubation buffer solutions that were used
were phosphate buffered saline (PBS) + 0.1%
bovine serum albumin (BSA) [buffer solution 1],
and PBS+ 6% gelafusal [buffer solution 2] (Merck,
Darmstadt,Germany, orRiedel-de-Haen,Germany).
Gelafusal was provided by Serumwerke Bernburg,
Germany, and o-phenylenediamine dihydrochlo-
ride by Sigma, St Louis, MO, USA. A horse anti-
serum against botulinum toxin type A reacting
with the neurotoxin complex was provided by the
UK National Institute for Biological Standards
and Control (NIBSC).
The 150 kD neurotoxin protein was purified
fromC. botulinum type A, strain ATCC 3502 (‘Hall
strain’), according to a modified protocol of
DasGupta and Sathyamoorthy.[20] It was dem-
onstrated by Western Blot that no complexing
proteins were present using an antiserum pro-
vided by the NIBSC. Antibodies to the 150 kD
neurotoxin were raised in rabbits and guinea pigs
(Biogenes, Berlin, Germany) according to a stan-
dard protocol. The neurotoxin was detoxified by
treatment with formaldehyde (0.4%, 15 days at
37C).
Complexing proteins of botulinum toxin type
A free from neurotoxin were prepared from the
botulinum toxin complex produced according to
the methods of Schantz and Johnson.[6] The
botulinum toxin complex was dialysed against
50mM TRIS (tris[hydroxymethyl] aminomethane)/
HCl pH = 7.9 and purified by column chromato-
graphy on Q sepharose (GEHealthcare, Freiburg,
Germany) by elution of the bound complexing
proteins with aNaCl gradient. Traces of BoNT/A
were removed by affinity chromatography. The
chromatography matrix was prepared by immo-
bilizing rabbit antibodies against BoNT/A on a
CNBr sepharose (GE Healthcare) according to
the instructions of the supplier. During the af-
finity chromatography step, BoNT/A was bound
to the affinity column whereas all complexing
proteins were eluted in the flow through. The
composition of the complexing proteins was not
changed after chromatography.
ELISA Procedure
A sensitive sandwich ELISA, which employed
rabbit and guinea pig antisera raised against the
150kDneurotoxin,was used tomeasure the amount
of BoNT/A in pharmaceutical preparations of
Botox, Dysport, and Xeomin.
Microtiter plates (Nunc 4 39 454) were coated
overnight at 2–8C with anti-150 kD neurotoxin
rabbit antisera diluted 1 : 1000 in 100mmol/L so-
dium carbonate, pH= 9.5. After washing five times
with buffer solution 1, unspecific binding was
blocked by incubation for 1 hour with PBS +
2% BSA. Vials of Botox (100 units), Dysport
(500 units), or Xeomin (100 units) were recon-
stituted with 1mL of buffer solution 1, and 100mL
(10 units) of Botox or Xeomin, or 30mL of the
Dysport (supplemented to a total volume of
100 mL with buffer solution 1) solution was pi-
petted into aMicrotiter plate well coated with the
anti-150 kD neurotoxin rabbit antisera and incu-
bated for 1 hour at 37C. Each vial was analyzed
in triplicate.
Wells were washed five times with buffer sol-
ution 1, incubated with the anti-150kD neurotoxin
guinea pig antiserum diluted 1 : 2000 in buffer solu-
tion 2 for 1 hour at 37C, then washed five times
with buffer solution 1 to remove unbound anti-
bodies. Bound 150kD neurotoxin antibodies were
detected by incubation for 1 hour at 37C with an
anti-guinea pig IgG peroxidase conjugate (Sigma,
A 7289) diluted 1 : 5000 in buffer solution 2. After
washing five times with buffer solution 1, the
concentration of the bound conjugate was deter-
mined by incubation with o-phenylenediamine
(16mmol/L) in 10mmol/L citrate buffer (pH= 5.0)
containing 0.06% H2O2. The color reaction was
stopped by the addition of 1mol/L sulphuric acid.
The optical density of each well was measured
at 490 nm on a Microtiter plate reader Spectra-
Max Plus (Molecular Devices, Sunnyvale, CA,
USA) operated via the ‘SoftMaxProGxP’ program.
To quantify the concentration of the 150 kD neu-
rotoxin, a standard curve was generated between
0.2 ng/mLand 1.6 ng/mLof the neurotoxin in steps
of 0.2 ng/mL. Figure 1 depicts a representative
standard curve covering a concentration range
between 0.2 and 1.6 ng/mL. On each Microtiter
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plate, a control sample was analyzed to assess the
validity of each assay. The ELISA was validated
according to the International Conference on
Harmonisation (ICH)[21] guidelines for linearity
of the standard curve, specificity, precision, ac-
curacy, and robustness. The specificity of the
ELISA was determined by analyzing purified
C. botulinum toxins type B (strain Okra), type C
(provided by Wako Ltd, Osaka, Japan) and type
E (strain ATCC 17854).
The amount of the 150kDneurotoxin in Botox
and Xeomin was determined by ELISA on two
different days. On day 1, two vials each of two
Botox batches (C2344C3 and C2384C3) and
two vials each of two Xeomin batches (61111
and 70604) were analyzed in parallel on the same
Microtiter plate. On day 2, two batches of Botox
(four vials of C2419 and six vials of C2385) and
five vials each of two Xeomin batches (61111
and 81208) were analyzed. For the comparison of
Dysport with Xeomin, five vials each of two
Dysport batches (678F and 689X) and two vials
of one Xeomin batch (61111) were analyzed.
Statistical Analysis
The concentration of BoNT/A in Botox,
Dysport, and Xeomin was reported using des-
criptive statistics. The coefficient of variation (CV)
was calculated by dividing the standard deviation
by the mean of all values, and is expressed as a
percentage.
The specific neurotoxin potency, defined as
the potency or biologic activity (units) per mass
of neurotoxin protein (ng) for Botox, Dysport,
and Xeominwas calculated based on the overall
mean concentration of the BoNT/A.
Results
ELISA Specificity
Purified C. botulinum toxins type B, type C,
and type E showed no signal at a maximum con-
centration of 100 ng/mL (data not shown), con-
firming the specificity of the ELISA assay for
BoNT/A.
None of the product’s excipients (sucrose and
lactose) interfered with the ELISA assay (data
not shown). Sodium chloride and human serum
albumin were present in the same concentration
in the samples. There was no reactivity when
£10 ng/mL of complexing proteins, purified from
the botulinum toxin complexes by affinity chro-
matography with immobilized neurotoxin, was
tested in the ELISA (data not shown). A recovery
of 97.3–100% was achieved by the ELISA when
0.9 ng/mL of the 150 kD neurotoxin protein was
added to 10 ng/mL of complexing proteins. The
ELISA detected denatured neurotoxin after heat
treatment (5 days after 80C).[22]
Botulinum Neurotoxin Type A Concentration
of Botox, Dysport, and Xeomin
The mean concentration of BoNT/A in the
two Botox batches, as determined by ELISA on
day 1, was 0.74 ng/vial (C2344C3) and 0.73 ng/
vial (C2384C3). For Xeomin, this was 0.45 ng/
vial for batch number 61111 and 0.43 ng/vial for

















Fig. 1. Standard curve of the ELISA specific for Clostridium botu-
linum neurotoxin type A (strain ATCC 3502).OD 490=optical density
at 490 nm.
Table I. Mean concentration of botulinum neurotoxin type A
(BoNT/A) in Botox and Xeomin analyzed by a sensitive sandwich
ELISA on day 1







CV = coefficient of variation.
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The repeat analysis on day 2 (table II) showed
a mean BoNT/A concentration of 0.76 ng/vial
(C2419) and 0.70 ng/vial (C2385) for the two
Botox batches. Both Xeomin batches (61111
and 81208) contained 0.44 ng/vial of BoNT/A;
therefore, the repeat analysis of batch number
61111 showed a comparable amount of BoNT/A
on days 1 and 2.
Overall, the mean concentration of BoNT/A in
Botoxwas 0.73 ng per 100 unit vial (CV = 3.5%),
whereas the mean concentration of BoNT/A in
Xeominwas 0.44ng per 100 unit vial (CV= 1.9%).
Analysis of the two Dysport batches showed
a mean concentration of BoNT/A of 3.5 ng/vial
(678F) and 2.97ng/vial (689X) [table III]. This cor-
responded to a mean concentration of 3.24ng/vial
of 500 units. Thus, 100 units of Dysport contained
0.65ng of the 150kD BoNT/A (CV= 11.4%).
Specific Neurotoxin Potency of Botox,
Dysport, and Xeomin
The specific potency of the 150kD BoNT/Awas
calculated as 137units/ng for Botox, 154units/ng
for Dysport, and 227units/ng Xeomin.
Discussion
This study has shown that 100 units of Botox,
Dysport, and Xeomin contain 0.73ng, 0.65ng
and 0.44 ng of BoNT/A, respectively. From these
results, we have been able to calculate the specific
neurotoxin potency for each preparation. The
highest specific neurotoxin activity was found in
Xeomin (227units/ng),Dysport had 154units/ng,
and Botox had the lowest biologic activity with
137 units/ng.
Interestingly, the 0.44 ng of neurotoxin protein
in Xeomin found in the current study is lower
than previously reported.[14] However, the higher
sensitivity and precision of the ELISA assay used
in the present investigation may have contributed
to this discrepancy.
As mentioned in the introduction, the 150 kD
neurotoxin is the only active pharmaceutical in-
gredient in Xeomin. Like Xeomin, the neuro-
toxin in Botox and Dysport (as part of the
toxic complex) is derived from the Hall strain of
C. botulinum type A and has an identical amino
acid sequence. However, it cannot be excluded
that there may be differences in the epitope
structure of the neurotoxin in Botox and Dys-
port compared with Xeomin because they are
prepared according to different procedures,[6,9]
which may affect their relative reactivity to the
antibody. Nevertheless, it may be speculated that
the differing epitopes (by structure, if there were
any) were not recognized by the applied anti-
bodies that are highly specific for the neurotoxin
in Xeomin. If that were the case, the binding of
the used antibodies to the neurotoxin in Botox
and Dysport would be lower in the ELISA.
Because the quantification of the ELISA depends
on the binding of the antibodies to the substance
to be analyzed, the relative concentration of the
neurotoxin determined in the assay would be
lower and the neurotoxin content in Botox and
Dysport would be even higher than that de-
scribed in this study. For a similar reason it
would be problematical to apply an immuno-
assay based on monoclonal antibodies, because
it has to be demonstrated that these antibodies
Table II. Mean concentration of botulinum neurotoxin type A
(BoNT/A) in Botox and Xeomin analyzed by a sensitive sandwich
ELISA on day 2







CV = coefficient of variation.
Table III. Mean concentration of botulinum neurotoxin type A
(BoNT/A) in Dysport and Xeomin analyzed by a sensitive sand-
wich ELISA






CV = coefficient of variation.
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react with respective epitopes of active as well as
inactive BoNT/A in all products.
Despite differences in specific neurotoxin ac-
tivity (defined as the biologic activity in units per
mass of neurotoxin protein), clinical studies have
shown that the efficacy of Xeomin and Botox
is comparable.[10-12] Dressler and colleagues[13]
also showed an equivalent potency of Botox and
Xeomin in a mouse LD50 bioassay. Together,
these results demonstrate that the amount of
neurotoxin in Botox and Xeomin exhibits the
same activity in the clinical environment as in the
standard mouse in vivo assay.[14]
From the results of the current study, one can
propose that the 0.44 ng neurotoxin protein in
100 units of Xeomin is as potent as the 0.73 ng
neurotoxin protein in 100 units of Botox. This
suggests that Botox contains a considerable
amount of inactivated or partly denatured/
inactivated neurotoxin - a suggestion that is
supported by a previous study that showed that
the 900 kD complex had a specific activity of
3 – 20%· 107 LD50 units per mg of protein.[6]
Thus, 100 units would correspond to 2.4–3.6 ng
clostridial protein, which differs markedly from
the 5 ng reported for Botox in its prescribing
information.[16] Of note, the presence of residual
denatured/inactive neurotoxin in Botox or Dys-
port (i.e. a higher dose of antigen) can, amongst
other factors, be associated with the stimulation
of neurotoxin neutralizing antibodies in some
patients.
The amount of neurotoxin in Botox can
also be estimated from the proportion of neuro-
toxin in the complex: the 150 kD neurotoxin
should be one-sixth of the 900 kD complex (i.e.
5 ng/6 = 0.83 ng), which is similar to the 0.73 ng
demonstrated in the present investigation. Our
calculation is supported by a patent application
filed by Allergan, which reported that the average
specific potency of the purified complex before
formulation was 28 pg protein/unit or 2.8 ng per
100 units.[23] Since Botox contains 5 ng and not
2.8 ng clostridial protein, is it likely that part of
the neurotoxin may be denatured,[24] possibly due
to the use of sodium chloride in the formulation,
which seems to be detrimental for activity during
the drying process.[25]
The current study found 3.24 ng per vial (500
units) of neurotoxin in Dysport, corresponding
to 0.65 ng per 100 units. Considering there is
4.35 ng of clostridial protein in a 500 unit vial of
Dysport, the proportion of the neurotoxin is
approximately 70%, with around 30%made up of
complexing proteins, and other clostridial pro-
teins.[9] This calculation is consistent with a rough
estimation of the proportion of the neurotoxin
from the electrophoresis of three batches of
Dysport.[9] Although all complexing proteins
were present in the drug substance,[9] the amount
of these proteins in the preparation seems to be
too low to form a high molecular weight complex
with all neurotoxin molecules, hence, a part of the
neurotoxin in Dysport seems to be present as a
free molecule.
In this study, a 100 unit vial of Xeomin
contained a mean concentration of BoNT/A
neurotoxin of 0.44 ng. The high specific potency
corresponds to high specific potency values in the
literature for the purified BoNT/A.[26] The reason
for the high specific activity in Xeominmight be
that no inactivation of the neurotoxin takes place
during the manufacturing process of the drug
product. As a result, the final Xeomin product
contains only the active neurotoxin. This is cor-
roborated by the finding that the active substance
before formulation and lyophilizing has the same
specific potency as the final product.[27]
Thus, although the amount of units of neuro-
toxin (specific biologic activity) is the same when
Botox or Xeomin is administered to the patient,
the amount of neurotoxin protein administered
is different. Patients treated with Botox receive
about 60% more of neurotoxin protein, which
represents denatured/inactive neurotoxin. This
means that the dose of antigen is higher, which
may be responsible for the formation of neutral-
izing antibodies leading to therapeutic failure. As
a consequence, this could exclude, for instance,
patients with dystonia or spasticity from receiv-
ing adequate treatment.
Conclusions
The current study has shown that of the three
products investigated, Xeomin contains the highest
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specific neurotoxin activity, followed by Dysport,
with Botox having the lowest biologic activity.
This result suggests that Xeomin contains only ac-
tive neurotoxin, whereas Botox is likely to contain
denatured/inactive neurotoxin.
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